The mTOR Inhibitor Rapamycin Mitigates Perforant Pathway Neurodegeneration and Synapse Loss in a Mouse Model of Early-Stage Alzheimer-Type Tauopathy.

The mTOR Inhibitor Rapamycin Mitigates Perforant Pathway Neurodegeneration and Synapse Loss in a Mouse Model of Early-Stage Alzheimer-Type Tauopathy.

The perforant pathway projection from layer II of the entorhinal cortex to the hippocampal dentate gyrus is especially important for long-term memory formation, and is preferentially vulnerable to developing a degenerative tauopathy early in Alzheimer's disease (AD) that may spread over time tr...

Full description

Bibliographic Details
Main Authors:	Robert Siman, Ryan Cocca, Yina Dong
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2015-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4634963?pdf=render

Similar Items

Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration
by: Henry Querfurth, et al.
Published: (2021-07-01)

mTOR Mysteries: Nuances and Questions About the Mechanistic Target of Rapamycin in Neurodegeneration
by: Nicholas G. Norwitz, et al.
Published: (2020-07-01)

The local mammalian target of rapamycin (mTOR) modulation: a promising strategy to counteract neurodegeneration
by: Diego Dolcetta, et al.
Published: (2019-01-01)

Cyclopamine and Rapamycin Synergistically Inhibit mTOR Signalling in Mouse Hepatocytes, Revealing an Interaction of Hedgehog and mTor Signalling in the Liver
by: Luise Spormann, et al.
Published: (2020-07-01)

Mechanistic Target of Rapamycin (mTOR) in the Cancer Setting
by: James T. Murray, et al.
Published: (2018-05-01)

Inhibition of mammalian target of rapamycin (mTOR) in epidermis
by: Sully, Katherine L.
Published: (2012)

Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease.
by: Patricia Spilman, et al.
Published: (2010-04-01)

Dendrite pathology and neurodegeneration: focus on mTOR
by: Adriana Di Polo
Published: (2015-01-01)

Correction: Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease
by: Patricia Spilman, et al.
Published: (2011-01-01)

Correction: Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease
by: Patricia Spilman, et al.
Published: (2011-01-01)

Correction: Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease.
by: Patricia Spilman, et al.
Published: (2011-01-01)

Correction: Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease.
by: Patricia Spilman, et al.
Published: (2011-01-01)

The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis
by: Jessica Lawrence, et al.
Published: (2018-03-01)

The Role of Mammalian Target of Rapamycin (mTOR) in Insulin Signaling
by: Mee-Sup Yoon
Published: (2017-10-01)

The role of the mammalian target of rapamycin (mTOR) in cytotoxic T lymphocytes
by: Hukelmann, Jens Ludger
Published: (2014)

The role of mammalian target of rapamycin (mTOR) in macrophage polarization
by: Byles, Vanessa A.
Published: (2016)

Mammalian Target of Rapamycin (mTOR) Pathways in Neurological Diseases
by: Michael Wong
Published: (2014-04-01)

Glial contributions to neurodegeneration in tauopathies
by: Cheryl E. G. Leyns, et al.
Published: (2017-06-01)

The mechanism of mTOR (mammalian target of rapamycin) in a mouse model of polycystic ovary syndrome (PCOS)
by: Yaba Aylin, et al.
Published: (2012-11-01)

Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer
by: Belinda Seto
Published: (2012-12-01)

Phosphorylated Mammalian Target of Rapamycin p-mTOR Is a Favorable Prognostic Factor than mTOR in Gastric Cancer.
by: Guo-Dong Cao, et al.
Published: (2016-01-01)

Associations of Alzheimer’s disease risk variants with gene expression, amyloidosis, tauopathy, and neurodegeneration
by: Meng-Shan Tan, et al.
Published: (2021-01-01)

Tauopathy and neurodegeneration: A role for stress
by: Jorge A. Sierra-Fonseca, et al.
Published: (2018-11-01)

Rapamycin directly activates lysosomal mucolipin TRP channels independent of mTOR.
by: Xiaoli Zhang, et al.
Published: (2019-05-01)

The mTOR inhibitor rapamycin has limited acute anticonvulsant effects in mice.
by: Adam L Hartman, et al.
Published: (2012-01-01)

Regulation of gene expression in hepatic cells by the mammalian Target of Rapamycin (mTOR).
by: Rosa H Jimenez, et al.
Published: (2010-02-01)

Blocking mTOR Signalling with Rapamycin Ameliorates Imiquimod-induced Psoriasis in Mice
by: Claudia Bürger, et al.
Published: (2017-06-01)

The Role of Mechanistic Target of Rapamycin (mTOR) Complexes Signaling in the Immune Responses
by: Ghada A. Soliman
Published: (2013-06-01)

Defining the clinical role of the mammalian target of rapamycin (mTOR) in lung cancer
by: Dhillon, Perminder Tony Singh
Published: (2010)

Structure of the human mTOR Complex I and its implications for rapamycin inhibition
by: Yip, Calvin K., et al.
Published: (2012)

Mammalian Target of Rapamycin (mTOR) and the Proteasome Attenuates IL-1β Expression in Primary Mouse Cardiac Fibroblasts
by: May-Kristin Torp, et al.
Published: (2019-06-01)

Targeting the core of neurodegeneration: FoxO, mTOR, and SIRT1
by: Kenneth Maiese
Published: (2021-01-01)

PREDICTION OF THE COURSE OF OSTEOARTHROSIS FROM mTOR (MAMMALIAN TARGET OF RAPAMYCIN) GENE EXPRESSION
by: E V Chetina, et al.
Published: (2012-02-01)

In Silico Strategy for Targeting the mTOR Kinase at Rapamycin Binding Site by Small Molecules
by: Serena Vittorio, et al.
Published: (2021-02-01)

Comparing the Effects of the mTOR Inhibitors Azithromycin and Rapamycin on In Vitro Expanded Regulatory T Cells
by: Marcus Bergström, et al.
Published: (2019-12-01)

Longitudinal imaging studies of tumor microenvironment in mice treated with the mTOR inhibitor rapamycin.
by: Keita Saito, et al.
Published: (2012-01-01)

Roles of the mammalian target of rapamycin, mTOR, in controlling ribosome biogenesis and protein synthesis
by: Iadevaia, Valentina, et al.
Published: (2012)

Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma
by: Carolina Caro-Vegas, et al.
Published: (2019-02-01)

Altered Synapse Stability in the Early Stages of Tauopathy
by: Johanna S. Jackson, et al.
Published: (2017-03-01)

Investigating neurodegeneration in a Drosophila model of tauopathy
by: Stubbs, Katy
Published: (2015)

Cannot write session to /tmp/vufind_sessions/sess_puprj4in91ev54vjhqe9pkt2eq